
WASHINGTON — President Trump boldly asserted Tuesday that his administration’s efforts to bring down drug prices had led to the largest drop in those figures in nearly half a century.
That’s not quite right.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Don’t put stuff on my Facebook feed that I have to pay to see or subscribe to. A waste of my time and isn’t going to happen. Makes me angry.
I have just been made aware of your publication thanks to NPR s site where I found an article imported from stat news. I was intrigued and wanted to know more but Immediately hit a roadblock i.e. Subscribe or forget it. Well unfortunately I cannot subscribe because I live on Social Security which Doesnot allow for Extras. I didnot and do not expect to get your publication for free. But to not allow me to get access to at least 2 or 3 articles a month seems penny wise and pound foolish, to paraphrase. I may not have much money but I do have quite a few friends whose interests, like mine, are wide ranging. And ‘word of mouth’ can be a powerful ‘thing’ 🙂. I could go on, but suffice to say, it honestly would be hard to recommend your site on the basis of one good article. So I ask that you reconsider your policy? and be alittle more generous with your writings availability. Thanks for reading this.